AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Hersima 440mg Injection

Prescription Icon
Prescription Required

Marketer

Alkem Laboratories Ltd

Salt Composition

Trastuzumab (440mg)

Overview Hersima 440mg Injection

Oncaspar, a 440mg injectable solution, combats breast and gastric cancers. Its mechanism involves targeting and destroying cancerous cells by suppressing HER2 protein activity. Administration is strictly via injection by a qualified healthcare provider. Dosage and frequency are determined by your physician based on your specific condition and may be adjusted. Adhere precisely to your doctor's prescribed regimen; incorrect usage or overdosage may lead to severe adverse effects. Therapeutic benefits may not be immediately apparent, potentially taking weeks or months; discontinue use only under your doctor's instruction. Common side effects include nausea, headache, skin rash, sleep disturbances, and infections. This medication can lower blood cell counts (red and white), increasing infection risk. Regular blood tests are essential to monitor blood cell levels, along with heart, liver function, and uric acid. Report shortness of breath, cough, chills, or limb swelling immediately. Inform your medical team of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is crucial for both partners throughout the treatment period.

Uses of Hersima 440mg Injection

Cancers affecting the breast and stomach.

Major Benefits of Hersima 440mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.

Common Side effects of Hersima 440mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Hersima 440mg Injection:

Administering this medication will be handled by your healthcare provider. Please do not attempt self-medication.

How Hersima 440mg Injection works:

Hersima 440mg Injection, a monoclonal antibody engineered from IgG1, targets HER2 receptors—human epidermal growth factor receptor 2 proteins—that drive excessive cell growth in breast and gastric cancers. By blocking HER2 activity, it eliminates cancer cells and disrupts multiple downstream signaling pathways crucial for cancer development.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concomitant use of Hersima 440mg Injection and alcohol may result in heightened somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Hersima 440mg Injection during pregnancy poses a confirmed risk to the fetus. Therefore, its use is contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential advantages outweigh the known hazards. Physician consultation is mandatory.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Hersima 440mg Injection while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

Hersima 440mg Injection's effect on driving ability is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

Hersima 440mg Injection appears safe for individuals with kidney impairment. Preliminary evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Insufficient data exists regarding the administration of Hersima 440mg Injection to individuals with hepatic impairment. Physician consultation is advised.

What if you forget to take Hersima 440mg Injection :

Should you inadvertently skip a Hersima 440mg Injection, seek medical advice.

Facts to Know About Hersima 440mg Injection

LabelValue
Type of Compound Single-clone antibody
Potential for Dependence None.
Medication Classification Cancer-fighting drugs
Mechanism of Action ErbB2-targeting monoclonal antibody

FAQs on Hersima 440mg Injection

Hersima 440mg Injection may cause several adverse reactions, including throat irritation, pyrexia, shivering, profound fatigue, pallor, epistaxis, and atypical bleeding or bruising. Additional side effects can encompass abdominal discomfort, convulsions, visual or auditory distortions, myalgia, and muscle spasms. Gastrointestinal distress such as nausea or emesis, anorexia, lassitude, tachycardia, and urine discoloration may also occur, along with oliguria, dysuria, painful urination, and other indicators of infection. Seek immediate medical attention if any of these symptoms develop.
Females capable of becoming pregnant must employ reliable birth control methods throughout their Hersima 440mg Injection treatment and for seven months following treatment completion. Pregnancy planning may commence seven months post-Hersima 440mg Injection therapy.
Individuals diagnosed with early-stage breast cancer should receive Hersima 440mg Injection for a duration of one year, or until disease progression, whichever event happens sooner. Treatment should not continue past this one-year timeframe in early breast cancer cases.
Hersima 440mg Injection does not require prior fasting. Administration must be supervised by an oncologist and performed exclusively by qualified medical personnel.
Hersima 440mg Injection is available in two distinct delivery methods: intravenous infusion (into a vein) and subcutaneous injection (under the skin). Confirming the correct formulation via product labeling before administration is crucial. The intravenous formulation is exclusively for intravenous infusion and must not be administered subcutaneously. A physician may alter a patient's Hersima 440mg Injection treatment between intravenous and subcutaneous routes as clinically indicated.
Hersima 440mg Injection is contraindicated in patients whose cancer cells lack HER2 expression. This monoclonal antibody selectively targets the human epidermal growth factor receptor 2 (HER2) protein, abundant on the surface of certain cancer cells. By binding to HER2, it inhibits cancer cell proliferation and metastasis. Consequently, its efficacy is limited to HER2-positive patients and offers no therapeutic benefit to those lacking HER2 expression.
The concomitant administration of Hersima 440mg Injection and anthracycline-based anticancer drugs (such as doxorubicin) carries a risk of cardiac complications. Therefore, pre-treatment and ongoing cardiac assessments are essential before and throughout the course of therapy.
Cardiac evaluations are necessary at treatment initiation. These assessments should recur every three months throughout treatment and every six months post-treatment cessation, continuing for 24 months following the final Hersima 440mg Injection. Patients with pre-existing cardiac conditions require evaluation every twelve weeks.
Hersima 440mg Injection
47,111
MRP 54,663
13% off